Skip to content

MAZE MAZE Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Septerna, Inc. logo
Septerna, Inc.SEPN
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.5B+205%
Enterprise value$1.36B
P/S

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's accrued expenses and other liabilities?
MAZE (MAZE) reported accrued expenses and other liabilities of -$4.07M in Q1 2026.